Biomedical applications of mRNA nanomedicine
Open accessAbstract
As an attractive alternative to plasmid DNA, messenger RNA (mRNA) has recently emerged as a promising class of nucleic acid therapeutics for biomedical applications. Advances in addressing the inherent shortcomings of mRNA and in the development of nanoparticle-based delivery systems have prompted the development and clinical translation of mRNA-based medicines. In this review, we discuss the chemical modification strategies of mRNA to improve its stability, minimize immune responses, and enhance translational efficacy. We also highlight recent progress in nanoparticle-based mRNA delivery. Considerable attention is given to the increasingly widespread applications of mRNA nanomedicine in the biomedical fields of vaccination, protein-replacement therapy, gene editing, and cellular reprogramming and engineering.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
The citation lists haven’t been fetched yet
References 215 · Cited by 125
Research works printed but not linked: 1
- [92][92] Kauffman K. J. Dorkin J. R. Yang J. H. Heartlein M. W. DeRosa F. Mir F. F. Fenton O. S. Anderson D. G. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs Nano Lett. 2015 15 7300 7306 26469188 10.1021/acs.nanolett.5b02497 · DOI
- Authors
- Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Shi, Jinjun
- Venue
- Nano Research
- Publisher
- Tsinghua University Press
- Published
- 2018-07-27
- Volume
- 11
- Issue
- 10
- Pages
- 5281-5309
- ISSN
- 1998-0000 (ISSN-L)
- 1998-0124
- PMC
- PMC6472920
- OpenAlex
- W2883278308
- Cited by
- 125
- References
- 215
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 18 · 2023: 18 · 2022: 26 · 2021: 21 · 2020: 16 · 2019: 7 · 2018: 1
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nano Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy
- National Cancer Institute (R01CA200900)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- mRNA therapeutics, mRNA stability, mRNA vaccines, protein replacement therapy, genome editing, cellular reprogramming, cell engineering, clinical translation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
